Core Insights - Quoin Pharmaceuticals has made significant advancements in its clinical programs, particularly for Netherton Syndrome and Peeling Skin Syndrome, with positive data emerging from ongoing studies [2][3][4] - The company closed a private placement financing in October 2025, raising up to $105.3 million to support operations and R&D efforts [1][4] - Sally Lawlor has been appointed as CFO to enhance the company's financial operations and support its commercialization strategy [1][3][7] Financial Highlights - As of September 30, 2025, Quoin reported a net loss of approximately $3.9 million for the third quarter and $11.5 million for the nine months, an increase from $2.3 million and $6.7 million in the same periods of 2024 [11][17] - The company had approximately $5.4 million in cash and cash equivalents, which, along with the recent financing, is expected to support operations into 2027 [10][11] - Operating expenses for the third quarter totaled approximately $4.0 million, with research and development costs significantly increasing compared to the previous year [17] Clinical and Regulatory Developments - The FDA awarded orphan drug designation to QRX003 for Netherton Syndrome, and pivotal studies for this treatment are set to begin enrollment in Q4 2025 [1][4] - The pediatric clinical program for Netherton Syndrome has been expanded based on positive long-term safety and efficacy data [1][2] - The NETHERTON NOW awareness campaign has gained significant traction, achieving over 1.5 million views within six months of its launch [1][8]

Core Viewpoint - Quoin Pharmaceuticals is highlighting the urgent need for effective treatments for Netherton Syndrome through the release of a new video featuring a patient advocate, emphasizing the severe impact of the disease on patients' lives and the ongoing development of their lead product candidate, QRX003 [1][5]. Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a commitment to addressing unmet medical needs [7]. - The company is advancing its lead product candidate, QRX003, through multiple pivotal clinical trials aimed at treating Netherton Syndrome [4][5]. Product Information - QRX003 is a topical lotion designed to normalize skin-shedding processes and strengthen the skin barrier, targeting the underlying issues caused by the absence of the LEKTI protein in Netherton patients [6]. - Recent data from ongoing studies of QRX003 have shown highly encouraging improvements in key clinical outcomes [4]. Patient Advocacy and Community Impact - Mandy Aldwin-Easton, featured in the video, shares her personal experiences with Netherton Syndrome, highlighting the chronic pain and emotional trauma associated with the disease [2][3]. - The company recognizes the significant physical, emotional, and financial toll that Netherton Syndrome places on patients and their families, reinforcing the importance of advocacy and awareness [4][5].

Core Insights - Quoin Pharmaceuticals reported significant clinical progress in its ongoing studies for QRX003, particularly for Netherton Syndrome and Peeling Skin Syndrome, with positive data indicating improvements in patient conditions [2][3][5] - The company received important regulatory designations, including Orphan Drug Designation from the European Medicines Agency and Rare Pediatric Disease Designation from the U.S. FDA, which are expected to accelerate the development of QRX003 [6][8] - The NETHERTON NOW campaign has been expanded to raise awareness about Netherton Syndrome, highlighting the urgent need for effective treatments [2][4][9] Clinical Developments - Positive clinical data from the pediatric Netherton Syndrome study showed significant improvements in skin condition and reduced itch after six months of treatment with QRX003, with no adverse events reported [3] - The Peeling Skin Syndrome study also reported positive outcomes after 12 weeks of treatment, with improvements in disease severity and quality of life metrics [5] - A second pivotal study for QRX003 targeting Netherton Syndrome has been cleared by the FDA, with recruitment expected to conclude by the end of Q1 2026 [7] Financial Overview - As of June 30, 2025, Quoin had approximately $7.8 million in cash and cash equivalents, which is projected to support operations into Q1 2026 [10] - The company reported a net loss of approximately $3.7 million for Q2 2025, an increase from a net loss of approximately $2.0 million in Q2 2024, primarily due to increased research and development expenditures [11][17] - Total operating expenses for the six months ended June 30, 2025, were approximately $7.75 million, compared to $4.60 million for the same period in 2024 [17]

Core Insights - Quoin Pharmaceuticals has released a new episode in its NETHERTON NOW video series, highlighting the severe burden of Netherton Syndrome in infants and children and the need for effective pediatric treatments [1][4] - The U.S. FDA has granted Rare Pediatric Disease Designation for Quoin's lead product candidate, QRX003, which aims to address the serious and underserved nature of Netherton Syndrome in pediatric patients [3][4] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a commitment to addressing unmet medical needs [6] - The company is developing a pipeline of four products targeting various rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, and others [6] Product Information - QRX003 is a topical lotion designed to promote a normalized skin-shedding process and strengthen the skin barrier in patients with Netherton Syndrome [5] - The mechanism of action for QRX003 involves a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor, which mimics the function of a specific protein called LEKTI [5] Expert Insights - Professor Jemima Mellerio, a recognized authority in dermatology, emphasizes the life-threatening challenges of Netherton Syndrome and the critical need for improved therapeutic options [2][3] - The experiences shared by Professor Mellerio in the NETHERTON NOW series highlight the challenges faced by children and families living with this condition [4]

Core Viewpoint - Quoin Pharmaceuticals has received Rare Pediatric Disease Designation from the FDA for its lead asset QRX003, aimed at treating Netherton Syndrome, a rare genetic disorder affecting children [1][3][4] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, with a pipeline that includes four products targeting various conditions [5] Regulatory Designations - The FDA's Rare Pediatric Disease Designation for QRX003 highlights its potential as a therapeutic candidate for an underserved pediatric population, following the Orphan Drug Designation granted by the EMA in May 2025 [2][3] Clinical Development - The company is focused on completing pivotal clinical studies for QRX003 and advancing it towards a New Drug Application (NDA) as the first potential treatment for Netherton Syndrome [3][5] Disease Background - Netherton Syndrome is a rare genetic disorder affecting approximately 1 in 200,000 newborns, with symptoms that can lead to severe skin inflammation and a mortality rate in infancy estimated at 10 to 20 percent [4]

Core Viewpoint - Quoin Pharmaceuticals Ltd. is set to release its financial results for Q1 2025 on May 13, 2025, which will include an operational update and financial highlights [1][2]. Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [3]. - The company aims to address unmet medical needs for patients and their communities [3]. - Quoin's pipeline includes four products in development targeting various rare and orphan indications such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa [3].